Health Canada's Low-Risk Drug Order: A Faster Path to Market for Sunscreens and OTC Products

Executive summary

On May 15, 2026, Health Canada published a Notice of Intent to make a Ministerial Class Exemption Order that would remove certain low-risk non-prescription drugs (NPDs) from the "new drug" requirements of Division 8 of the Food and Drug Regulations. If a product is on List D and complies with a published Health Canada monograph, its sponsor could apply for a Drug Identification Number (DIN) under Division 1 without a Notice of Compliance. That change would cut a review pathway that today can run up to 300 days and cost more than $600,000.

The Order would cover ten familiar product categories: sunscreens (primary and secondary), acne therapies, anti-dandruff products, antiperspirants, antiseptic skin cleansers, athlete's foot treatments, diaper-rash products, medicated skin care, oral-health products such as toothpastes and mouthwashes, and throat lozenges. Eligibility is tied tightly to monograph conformance, so the new speed comes with strict technical conditions. Health Canada is accepting comments until July 14, 2026, and is specifically asking industry which new ingredients should be added to its monographs. Companies that want a say should prepare evidence now.

Introduction

For years, a sunscreen active sold safely across the United States or the European Union could not reach Canadian shelves without clearing the same regulatory bar as a prescription medicine. That is the friction Health Canada is now trying to remove.

The proposed Order is part of a broader push to modernize how Canada regulates self-care products and to reduce what the federal government calls "red tape." For consumer health and personal care companies, including international brands that have held back from the Canadian market, it could open a faster and far less expensive route to commercialization. For regulatory and quality teams, it sets up a familiar trade-off: a lighter pathway in exchange for disciplined conformance to a monograph.

This article explains what the Order does, who it affects, where the compliance risks sit, and what your team should do before the July 14 comment deadline.

What is the proposed Ministerial Order?

Direct answer: The proposed Ministerial Class Exemption Order would exempt low-risk non-prescription drugs listed on List D from the Division 8 ("new drug") prohibitions and requirements of Part C of the Food and Drug Regulations, provided the product complies with an applicable Health Canada monograph. Sponsors could then seek market authorization through a Division 1 DIN application instead of a Notice of Compliance.

Under the current rules, any drug that contains a medicinal ingredient not previously authorized in Canada is treated as a "new drug" under Division 8, whether it is a prescription oncology product or an over-the-counter sunscreen. Both face the same demands: significant safety and efficacy data, a review timeline of up to 300 days, and authorization costs that Health Canada estimates can exceed $600,000.

An expedited route already exists for many non-prescription drugs through Health Canada's monograph system under Division 1. A monograph sets out the permitted medicinal ingredients, concentrations, indications, directions for use, and conditions of use such as warnings. If a product meets every parameter in the monograph, it can be authorized without additional evidence. The catch is that this route has been closed to products containing ingredients that are new to Canada, even where those ingredients have a long, well-documented record of safety abroad. The Order is designed to close that gap.

Why does it matter?

Direct answer: It matters because the Order could shorten timelines, sharply lower costs, and give Canadians access to actives already trusted in other markets, while shifting the centre of gravity in regulatory work from large data packages to precise monograph conformance.

Health Canada frames the change around four goals: improving access to products that treat and prevent common conditions, supporting faster market access and competition, reducing barriers and cost for industry, and maintaining proportionate oversight of genuinely low-risk products.

There is also a supply-resilience angle. Health Canada notes that Canadians rely heavily on these products imported from the United States, with estimates of more than 70 percent of imports in these categories coming from the U.S. A pathway that makes it easier to bring in actives proven in the EU and other markets is intended to diversify supply and reduce the risk of shortages. The proposal grew in part out of engagement through the Canada-EU Regulatory Cooperation Forum and consultation with domestic industry.

The Order would also feed Health Canada's Red Tape Reduction initiative, contributing to the themes of reducing trade barriers and enhancing regulatory flexibility.

Which products are covered?

Direct answer: The Order applies to the low-risk non-prescription drug categories found on List D (the List of Certain Non-prescription Drugs for Distribution as Samples). These are cosmetic-like, self-selected products used for routine self-care.

Product category	Typical examples
Sunscreens (primary and secondary)	Lotions, sprays, and day creams or cosmetics with SPF
Acne therapy products	Benzoyl peroxide and salicylic acid washes and gels
Anti-dandruff products	Medicated shampoos
Antiperspirants	Aluminum-salt sticks, roll-ons, and sprays
Antiseptic skin cleansers	Hand and skin antiseptic washes
Athlete's foot treatments	Topical antifungal creams and powders
Diaper-rash products	Zinc oxide and barrier creams
Medicated skin care products	Treatments for minor skin conditions
Oral-health products	Fluoride toothpastes and therapeutic mouthwashes
Throat lozenges	Medicated lozenges for minor throat irritation

Health Canada has said it intends to update its monographs over time and add new medicinal ingredients, which would gradually expand the range of products able to use the exemption. In other words, List D defines the categories, but the live monographs define what can actually move through the faster route on any given day.

How does the new pathway work?

Direct answer: Eligible products would leave the Division 8 new-drug stream and instead be authorized through a Division 1 DIN application, on the strength of full conformance with a Health Canada monograph rather than a bespoke data package.

The practical sequence looks like this:

Confirm the product sits in a List D category. If it does not, the exemption does not apply and the standard pathway still governs.
Identify the applicable Health Canada monograph and confirm the medicinal ingredient, concentration, indication, directions, and warnings all fall within its parameters.
Where the ingredient is not yet in a monograph, assess whether it could be added, and gather the foreign safety, efficacy, and quality evidence that would support a monograph update.
Prepare and submit a Division 1 application for a DIN without a Notice of Compliance.
Meet ongoing Division 1 obligations, including establishment licensing, labelling, and Good Manufacturing Practices.

It is worth stressing what does not change. Exemption from Division 8 is not exemption from regulation. Products still need a DIN, still need compliant bilingual labelling, and still must be made under Good Manufacturing Practices at a licensed establishment. The relief is targeted at the new-drug review burden, not at the day-to-day quality and labelling rules that protect consumers.

How does it affect compliance?

Direct answer: The Order moves the compliance burden from generating large clinical and chemistry data packages toward demonstrating exact, defensible conformance with a monograph. That is a different discipline, and getting it wrong has consequences.

A monograph is unforgiving by design. A concentration slightly above the permitted range, an indication that drifts beyond the approved wording, a missing or altered warning, or a combination of actives the monograph does not contemplate can all push a product back into the new-drug stream or expose it to compliance action after launch. For teams used to building data dossiers, the skill set shifts toward meticulous mapping, formulation control, and labelling precision.

Classification also still matters. Whether a given product is a cosmetic, a non-prescription drug, or a natural health product determines which rules apply in the first place, and the cosmetic-drug interface remains one of the most common areas of confusion for brands entering Canada.

The consultation: what Health Canada is asking

Health Canada is inviting written comments on the proposed approach until July 14, 2026, and will hold targeted stakeholder sessions after publishing the notice. The department posed two guiding questions:

Would being exempt from Division 8 requirements encourage you to seek market authorization for, or manufacture, your List D low-risk non-prescription drug in Canada?
Does your company use any new medicinal ingredients in List D products in foreign jurisdictions, with supporting evidence of safety, effectiveness, and quality that could be used to update a Health Canada monograph? If so, which ingredients?

The second question is the strategic one. Health Canada is openly asking industry to nominate ingredients for future monograph updates. A company that submits a well-organized evidence package now has a real opportunity to shape which actives become eligible for the faster route, ahead of competitors. Comments and supporting evidence go to Health Canada's Natural and Non-prescription Health Products Directorate by email before the deadline.

Compliance checklist: getting ready for the new pathway

Use this checklist to assess readiness whether or not you plan to file a comment:

Confirm whether each product falls within a List D category.
Identify the applicable Health Canada monograph for each product.
Map the medicinal ingredient, concentration, indication, directions, and warnings against the monograph parameters.
Flag any ingredient that is not yet in a Canadian monograph but is authorized abroad.
Assemble foreign safety, efficacy, and quality evidence for those ingredients.
Verify bilingual labelling meets Division 1 requirements.
Confirm your manufacturing site holds the appropriate establishment licence and operates under Good Manufacturing Practices.
Decide whether to submit a comment or ingredient nomination before July 14, 2026.
Build a transition plan for the eventual move to the "Simplifying Part C" framework.

Common mistakes to avoid

Assuming exemption means deregulation. The Order removes the Division 8 review, not the obligation to hold a DIN, label correctly, and manufacture under GMP. Treating it as a free pass invites a compliance finding.

Reading the monograph loosely. Monograph conformance is binary. "Close enough" on a concentration, indication, or warning is not conformance, and a single deviation can disqualify the product.

Misclassifying the product. A product positioned as a cosmetic may actually be a drug, or vice versa. Settle classification first, because it decides which framework applies.

Missing the strategic comment window. Companies that stay silent leave monograph updates to others. If your portfolio depends on a newer active, the consultation is the moment to make the case.

Forgetting the sunset. Because the Order is temporary, a market-entry plan that ignores the coming Part C amendments will need to be reworked later.

Frequently asked questions

When do comments close?

Health Canada is accepting comments until July 14, 2026, submitted by email to its Natural and Non-prescription Health Products Directorate.

Does the Order remove the need for a DIN?

No. Eligible products would still require a Drug Identification Number through a Division 1 application. The Order removes the Division 8 new-drug review, not the DIN itself.

Which products are eligible?

Low-risk non-prescription drugs in the List D categories: sunscreens, acne therapies, anti-dandruff products, antiperspirants, antiseptic skin cleansers, athlete's foot treatments, diaper-rash products, medicated skin care, oral-health products, and throat lozenges, provided each complies with an applicable Health Canada monograph.

What if my ingredient is not in a monograph yet?

The product would not currently qualify, but Health Canada plans to add ingredients to its monographs over time and is asking industry to nominate ingredients, with supporting evidence, during the consultation.

Is the faster pathway permanent?

No. The exemption would apply until the planned "Simplifying Part C of the Food and Drug Regulations" amendments come into force, after which the Order would be repealed.

How much could it save?

Health Canada notes the current new-drug pathway can take up to 300 days and cost more than $600,000. The Order is intended to reduce or eliminate additional data requirements, shorten timelines, and significantly lower authorization costs for eligible products.

How MFLRC can help

MF License & Regulatory Consultants helps consumer health, personal care, sunscreen, and natural-health companies turn regulatory change into market access. With more than twenty years of Health Canada quality and regulatory experience, our team supports clients across the full lifecycle of a non-prescription drug. For this Order specifically, we can:

Map your portfolio to List D and the applicable monographs, producing a clear conformance gap assessment for each product.
Resolve classification questions at the cosmetic, drug, and natural-health-product interface before they cause delays.
Build ingredient-nomination submissions and consultation comments, organizing the foreign safety, efficacy, and quality evidence Health Canada is asking for.
Prepare Division 1 DIN applications, labelling, and establishment-licensing files.
Strengthen quality systems and GMP readiness through quality assurance and compliance support and audit services, so your manufacturing meets Division 1 expectations.

We work with natural health product, cosmetics and personal care, and pharmaceutical clients entering or expanding in Canada, drawing on deep regulatory affairs and licensing expertise.

If this proposal affects your products, the time to act is before July 14, 2026. Contact MFLRC for guidance tailored to your portfolio.

Book a Consultation with MFLRC

Conclusion

Health Canada's proposed Ministerial Order is a meaningful shift for the consumer health and personal care sector. By exempting low-risk non-prescription drugs on List D from the new-drug requirements of Division 8, the department is offering a faster, cheaper route to market for actives already proven safe and effective abroad, from sunscreens to oral-health products. The relief is real, but it is conditional: eligibility depends on exact monograph conformance, the product still needs a DIN and compliant manufacturing, and the exemption is a temporary bridge to the broader Part C reforms.

The most important date is July 14, 2026. The consultation is not only a chance to comment on the approach but an opportunity to nominate the ingredients that will define which products qualify. Companies that prepare their evidence and map their portfolios now will be best placed both to influence the outcome and to move quickly once the Order takes effect.